Dr. Stefanie Kesting appointed as CEO of Thyssengas
Dortmund, 06.01.2026
As of January 1, 2026, Dr. Stefanie Kesting has been appointed as the new Chief Executive Officer (CEO) of Thyssengas GmbH. She succeeds Dr. Thomas Gößmann, who will retire at the end of February 2026 after nearly nine years at the helm of the company. The leadership transition was announced in autumn 2025.
Thyssengas is facing the biggest turning point in its history: in addition to natural gas, hydrogen and other green gases are to flow through the transmission network in increasing quantities in the future. The transmission system operator wants to lay the foundation for a new energy market. In this decisive phase, 49-year-old energy manager Dr. Stefanie Kesting is taking over the leadership of the company.
“In the coming years, it will be determined whether we succeed in the transformation and in establishing a new kind of resilience in energy supply. As a transmission system operator, we bear a special responsibility: We create the gas infrastructure that industry, SMEs, and regions need for their path toward a secure and climate-neutral future. At the same time, we bring our experience, our regional network, and our close ties to our western neighbours to actively shape this transition,” says Kesting. “Building the hydrogen core network is an important component, but it is only part of the picture. We need to think holistically: more regionally, across sectors, and always with a focus on what our customers and partners on the ground need for a secure energy supply and their individual decarbonization path. I am very much looking forward to driving this process forward together with the strong Thyssengas team.”
Dr. Stefanie Kesting has many years of leadership experience in the energy sector – including positions at international energy companies such as DNV, E.ON, and Uniper, and most recently at plant manufacturer Neuman & Esser, where she served as Managing Director responsible for the Energy Project Solutions business unit. Her professional focus has been on renewable gases, hydrogen, and CO₂ technologies for many years. In addition, she has served and continues to serve on several international supervisory boards in the energy and industrial sectors.
With the appointment of Dr. Stefanie Kesting, the Thyssengas management board will temporarily consist of:
- Dr. Stefanie Kesting, Chief Executive Officer
- Dr. Thomas Becker, Chief Financial Officer
- Dr. Thomas Gößmann, Member of the Management Board
As of March 1, 2026, the management board will comprise Dr. Stefanie Kesting (CEO) and Dr. Thomas Becker (CFO).
Contacts
Peter AlexewiczHead of Communications and Political AffairsThyssengas Gmb
Emil-Moog-Platz 13
44137 Dortmund
Images
About Thyssengas
Thyssengas GmbH is a German transmission system operator. The company, which celebrated its 100th anniversary in 2021, is headquartered in Dortmund. Thyssengas operates a gas network of approximately 4,400 kilometers – primarily in North Rhine-Westphalia, with some lines in Lower Saxony. Through this network, downstream distribution system operators as well as industrial companies and power plants are supplied. For a climate-neutral future, Thyssengas is focusing on hydrogen as a gaseous energy carrier. The Dortmund-based network operator is actively involved in numerous initiatives and is investing specifically in converting its pipeline system to enable a rapid hydrogen ramp-up as part of the energy transition. The company currently employs around 550 people at eight locations within its network area.
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
Acousia Announces Completion of Patient Enrollment in Phase 2 PROHEAR Study Evaluating ACOU085 (INN: Bimokalner) for the Prevention of Cisplatin-Induced Ototoxicity8.1.2026 09:00:00 CET | Press Release
Tübingen, Germany, January 8, 2026 Acousia Therapeutics GmbH, a clinical-stage biotechnology company developing treatments for acute and chronic inner ear hearing loss, announced the completion of patient enrollment in its Phase 2 PROHEAR clinical study. ACOU085 (INN: Bimokalner) is a proprietary, first-in-class small molecule that has demonstrated robust and reproducible efficacy across multiple preclinical hearing loss models, including drug-induced ototoxicity. The PROHEAR Study is a double-blind, randomized, placebo-controlled, split-body, multicenter Phase 2 trial. It enrolled young male patients with metastatic testicular cancer who are scheduled to receive cisplatin-based chemotherapy. While cisplatin is a highly effective chemotherapeutic agent, cumulative doses of ≥300 mg/m² lead to clinically meaningful, permanent hearing loss in the majority of patients. Fifteen leading university hospitals in Germany are participating in this interdisciplinary study. Patients are randomized
30 Years of European Spas: Nature, Natural Remedies and Climate Health as Europe’s Unique Strength7.1.2026 08:20:00 CET | Press Release
To mark its 30th anniversary, the European Spas Association (ESPA) has released a special commemorative publication highlighting the strategic role of Europe’s medical spas and climate-health resorts in an era defined by prevention, longevity and sustainable wellbeing. The anniversary edition underlines how natural remedies, therapeutic landscapes and evidence-based spa medicine represent a distinctive European strength with growing relevance for public health systems. Across Europe, medical spas are increasingly recognised as complementary health infrastructures supporting prevention, rehabilitation and long-term quality of life. “Medical spas today are strategic health infrastructures supporting prevention, rehabilitation and long-term wellbeing,” says Dr Siyka Katsarova, President of ESPA and Advisor to the EU’s New Lifestyle Strategy. The publication showcases Europe’s exceptional therapeutic diversity — ranging from thermal and mineral waters, climate therapy and thalassotherapy t
Forum for a self-reliant and self-determined Europe - the "Sovereign Europe Forum"23.12.2025 07:00:00 CET | Press Release
Munich, 22 December 2025 – Entrepreneurs, top managers and leaders from United Europe e.V. and European Forum Alpbach (EFA) are founding the Sovereign Europe Forum i.G.
Digital Subsidiary of Austrian State Printing Company Wins Infrastructure Tender for German EU Digital Identity Wallet22.12.2025 15:00:56 CET | Press Release
youniqx Identity, a digital subsidiary of the Austrian State Printing Company (OSD), has won a Europe-wide tender, together with partner companies, for the infrastructure of the German EU Digital Identity Wallet (EUDI-Wallet). EU member states are required by EU regulations to provide a national version of an EU-wide valid EUDI-Wallet by the end of 2026. Citizens will be able to use the EUDI-Wallet to prove their personal identity throughout the EU
MT Raceteam entering Ligier European Series with 16 year old Marcus Terkildsen / attractive partnerships and high visibility available18.12.2025 13:28:55 CET | Press Release
Copenhagen, Dec 18, 2025 - MT Raceteam is proud to announce its 2026 entry into the prestigious Ligier European Series, where the team will compete in a state-of-the-art Ligier JS2 R supplied by 23 Events Racing. This marks an important milestone for both the team and sixteen-year-old Danish driver Marcus Terkildsen as they step into one of Europe’s most competitive championships.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom